Supernus Pharmaceuticals (SUPN, Drugmakers) Stock Valuation & Fair Value
Mixed on our testsSupernus Pharmaceuticals (SUPN, Drugmakers) trades at a current P/E of 9.2, about 56% below its historical normal valuation, with a forward growth estimate of 32.0% and a PEG of 0.29. Priced at its historical normal P/E of 20.8 on the same blended earnings, the 2026-11-06 close of $26.16 corresponds to about $59.10 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $26.16 at the Nov 6 close, 3.2% below the 20-day average ($27.03) and 4.0% below the 50-day ($27.26).
- RSI (14) at 39.9.
- 52-week range $22.33 to $32.46: the price is 19.4% below the high and 17.2% above the low.
The Street vs SeerForecast
Wall Street's mean price target for SUPN is $60.50 across 4 analysts, 131.3% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- Misses analyst estimates often (45%)
Verdict history
tickerseer's rating has been mixed on our tests since 2026-07-31.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, and the cheapest and dearest.
Show all 29 readings
Frequently asked questions
Is Supernus Pharmaceuticals stock overvalued?
At a current P/E of 9.2 versus its historical normal P/E of 20.8, Supernus Pharmaceuticals trades about 56% below its typical valuation, with a PEG of 0.29 on 32.0% forward growth. tickerseer currently rates it mixed on our tests.
What is Supernus Pharmaceuticals's fair value and PEG?
Supernus Pharmaceuticals trades at a current P/E of 9.2 against a historical normal P/E of 20.8, a PEG of 0.29, and a forward growth estimate of 32.0%. Priced at its historical normal P/E of 20.8 on the same blended earnings, the 2026-11-06 close of $26.16 corresponds to about $59.10 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Supernus Pharmaceuticals changed?
tickerseer's rating has been mixed on our tests since 2026-07-31.
What is the analyst price target for Supernus Pharmaceuticals?
The mean Wall Street price target for Supernus Pharmaceuticals is $60.50 across 4 analysts, 131.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.